SCHEMBL10246983

SCHEMBL10246983

O=C(NO)c1ccc2c(c1)CCCC2NC(=O)c1cnc2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TAS1R3 Q7RTX0 5/20 0.48
TAS1R1 Q7RTX1 5/20 0.48
TAS1R2 Q8TE23 3/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 2/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
TAOK1 Q7L7X3 1/20 0.45
TAOK3 Q9H2K8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085186 0.85 CNR1 (0.60) ALDH1A1TAS1R3TAS1R1TAS1R2POLB
SCHEMBL10249684 0.78 HTT (0.62) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL10247010 0.78 HDAC3 (0.54) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL10247155 0.76 LMNA (0.77) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL10246997 0.75 LMNA (0.62) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL10246961 0.75 RAB9A (0.54) ALDH1A1TAS1R3TAS1R1TAS1R2POLB
SCHEMBL10246947 0.75 CHRNA7 (0.49) ALDH1A1TAS1R3TAS1R1TAS1R2POLB
SCHEMBL10252064 0.74 TAS1R3 (0.49) ALDH1A1TAS1R3TAS1R1TAS1R2POLB
SCHEMBL10246865 0.73 LMNA (0.54) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A
SCHEMBL10252477 0.73 DHODH (0.54) ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 ALDH1A1 676/4885TAS1R3 3594/4885TAS1R1 3179/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 ALDH1A1 202/4885TAS1R3 3997/4885TAS1R1 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.